Bluebird Bio stock rises 62%, FDA committee supports treatments
June 10, 2022 at 17:40 PM EDT
Shares of Bluebird Bio Inc. rally more than 60% after news that a U.S. FDA committee supports two of the company's gene therapies.
Photography by Christophe Tomatis